Lenalidomide Alkaloid-Int

Lenalidomide, the active ingredient in Lenalidomide Alkaloid-Int, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and certain myelodysplastic syndromes in adult patients. The medication works by modulating the immune system and inhibiting tumor growth pathways, offering a targeted therapeutic option in hematologic oncology.

GNH USA supplies Lenalidomide Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, clinics and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders. - Multiple Myeloma: improves progression‑free and overall survival in newly diagnosed and relapsed patients. - Relapsed/Refractory Multiple Myeloma: provides disease control when prior therapies have failed. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves blood counts.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions that are usually self‑limited.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism requiring immediate treatment. - Severe neutropenia or thrombocytopenia: markedly low blood counts that can lead to bleeding or infection. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers during therapy.

Lenalidomide requires careful risk management and monitoring. - Pregnancy: contraindicated; teratogenic risk (Category X). - Thrombosis risk: assess and consider prophylaxis, especially in patients with additional risk factors. - Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dose in patients with reduced clearance. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Store at room temperature: keep in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Immunosuppressants (e.g., cyclosporine): may amplify immunomodulatory effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - NSAIDs: can increase risk of thrombosis when combined. - Live vaccines: reduced efficacy and potential safety concerns.